3604.T Stock Bounces Back 0.08% in Pre-Market, Medical Supplier Holds Steady

Kawamoto Corporation’s 3604.T stock is showing early strength in pre-market trading on April 16, 2026, gaining 0.08% to reach ¥1,198 on the JPX exchange. The medical instruments and supplies manufacturer, headquartered in Osaka, Japan, is demonstrating resilience after recent market pressures. With a market cap of approximately 6.94 billion JPY and trading volume at 9,000 shares, the stock is positioning itself for potential recovery. Kawamoto’s diversified product portfolio—spanning surgical sponges, disposable medical products, and healthcare equipment—continues to support investor confidence in this healthcare sector player.

3604.T Stock Price Action and Technical Setup

Kawamoto Corporation’s 3604.T stock opened at ¥1,198 with a modest gain of ¥1.0 from the previous close of ¥1,197. The stock is trading within a tight range, with the day’s low at ¥1,198 and high at ¥1,200, reflecting controlled pre-market activity. The 50-day moving average sits at ¥1,196.54, suggesting the stock is trading near its short-term support level. However, the broader picture shows significant recovery potential: the 52-week high stands at ¥1,486, while the 52-week low is ¥603, indicating the stock has already recovered 98.8% from its yearly lows. This oversold bounce pattern is typical for medical supply stocks experiencing sector-wide volatility.

Valuation Metrics Show Attractive Entry Point for 3604.T

The 3604.T stock trades at a P/E ratio of 15.04, which is reasonable for a healthcare company with stable earnings. The price-to-sales ratio of 0.42 suggests the stock is trading at a discount relative to revenue generation, making it attractive for value-focused investors. With earnings per share (EPS) of 79.67 JPY, Kawamoto demonstrates solid profitability despite operating in a competitive medical supplies market. The price-to-book ratio of 0.91 indicates the stock is trading below book value, another positive signal for oversold recovery plays. These metrics collectively suggest that 3604.T may offer compelling value after recent weakness, particularly for investors seeking exposure to Japan’s healthcare sector.

Market Sentiment and Trading Activity for 3604.T

Trading Activity: Current volume of 9,000 shares represents only 38.3% of the average daily volume of 23,516 shares, indicating light pre-market participation. This lower-than-average activity is typical for early trading sessions and may suggest that institutional buying could accelerate once the main session opens. The relative volume compression creates potential for momentum once broader market participation increases.

Liquidation Dynamics: The stock’s recovery from ¥603 to ¥1,198 reflects a reversal of previous liquidation pressure. With 5.8 million shares outstanding and a market cap of 6.94 billion JPY, Kawamoto maintains adequate liquidity for institutional investors. The current ratio of 1.76 indicates solid short-term financial health, reducing concerns about forced selling or distressed liquidation scenarios.

Kawamoto Corporation’s Business Fundamentals and Sector Position

Kawamoto Corporation manufactures and supplies medical and hospital products primarily serving the Japanese market, with exports to Asia, the Middle East, Africa, Europe, and the Americas. The company’s product range includes surgical sponges, neurosurgical pads, oral care products, disposable medical items, surgical equipment, and sanitary products. Founded in 1914 and listed on JPX since 2003, Kawamoto operates with 4,360 full-time employees under CEO Makoto Fukui. As a subsidiary of Air Water Inc., the company benefits from parent company support and distribution networks. Track 3604.T on Meyka for real-time updates on this established healthcare supplier.

Financial Health and Debt Management of 3604.T Stock

Kawamoto’s debt-to-equity ratio of 0.74 is moderate for a manufacturing company, indicating balanced capital structure. The interest coverage ratio of 43.13 demonstrates exceptional ability to service debt obligations, providing confidence in financial stability. With cash per share of 225.18 JPY, the company maintains adequate liquidity reserves. The working capital of 6.45 billion JPY supports operational flexibility and inventory management. However, the days sales outstanding of 216 days suggests extended payment terms with customers, which is common in healthcare supply chains. The cash conversion cycle of 192.6 days indicates capital is tied up longer than ideal, but this is manageable given the company’s strong cash position and profitability.

Meyka AI Grade and Investment Outlook for 3604.T

Meyka AI rates 3604.T with a grade of B and a HOLD recommendation based on a score of 65.11. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating reflects mixed signals: strong ROE and ROA scores support the positive outlook, while weak DCF and debt metrics warrant caution. The PEG ratio of 1.58 suggests reasonable valuation relative to growth prospects. These grades are not guaranteed and we are not financial advisors. For investors seeking exposure to Japan’s healthcare sector, 3604.T presents a balanced risk-reward profile during this pre-market recovery phase.

Final Thoughts

Kawamoto Corporation’s 3604.T stock is demonstrating classic oversold bounce characteristics in pre-market trading, gaining 0.08% to ¥1,198 on the JPX. The stock’s recovery from its ¥603 yearly low to current levels reflects renewed investor interest in this established medical supplies manufacturer. Valuation metrics including a P/E of 15.04, price-to-sales of 0.42, and price-to-book of 0.91 all suggest the stock trades at attractive levels. The company’s solid fundamentals—including strong interest coverage, adequate liquidity, and diversified product portfolio—support the recovery narrative. However, investors should monitor trading volume and broader healthcare sector trends. The Meyka AI B-grade HOLD rating reflects balanced risk-reward dynamics. This pre-market strength may signal institutional accumulation ahead of the main session, making 3604.T worth watching for value-oriented healthcare investors.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.